KPTI News and Press, Karyopharm Therapeutics Inc. From 08/04/20

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2020 Q2 earnings Read more ...

NEWTON, Mass. , Aug. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020 . In addition, Karyopharm highlighted select corpora...

NEWTON, Mass. , July 28, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday, August 4, 2020 . Karyopharm's management team will host a confe...

NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) seeking approval fo...

Karyopharm ( KPTI ) is a commercial-stage pharma company that already markets its leading compound, Xpovio or selinexor, in 2 different cancer indications. Karyopharm fits the model I look for of companies with a novel technology platform that’s already clinically-validated and is tradi...

Karyopharm Collaborates with National Cancer Institute for XPOVIO Research Karyopharm Therapeutics Inc. ( KPTI ) announced that it has inked a new collaboration with National Cancer Institute. The partnership will mainly focus on developing XPOVIO, an oral Selective Inhibitor of Nuclear ...

Karyopharm Therapeutics (NASDAQ: KPTI ) will collaborate with the National Cancer Institute (NCI) to explore the potential of Xpovio (selinexor) in a wider range of cancers. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...

NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Cance...

Karyopharm Therapeutics (NASDAQ: KPTI ) expects preliminary Q2 net product sales for XPOVIO (selinexor) to be ~$18.5M, (+15% Y/Y), topping Bloomberg average estimate of $17.5M (range $17M to $19M). More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move, ...